Questions arise about robotic surgery's cost, effectiveness
In the dozen years since the Da Vinci robot has been approved for surgeries in the United States, it's been embraced by health care providers and patients alike. Surgeons routinely use the multi-armed metal assistant to remove cancerous prostate glands and uteruses, repair heart valves and perform gastric bypass operations, among many other procedures. Lately a key study and reports of problems have raised questions about robotic surgery's safety and cost-effectiveness, leading to a review of the Da Vinci system by the Food and Drug Administration and causing some experts to wonder whether the benefits of undergoing robot-assisted surgery may have been overstated.
- Sharp HealthCare Leaves Pioneer ACO Program
- Acute Kidney Injury Gets New Focus
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- PCI: Concerns Mount About Appropriateness
- Transforming Cancer Care
- MA an Insurance Proving Ground for Providers
- mHealth Tackles Readmissions